Movano health on track to file first fda submission for its smart ring's spo2 and heart rate data following successful pivotal hypoxia trial

Preliminary results demonstrated high accuracy of spo2  and heart rate data in its pivotal hypoxia trial, bringing the company one step closer to developing a medical device pleasanton, calif. , dec. 14, 2022 /prnewswire/ -- movano health (nasdaq:move), a purpose-driven healthcare solutions company at the intersection of medical and consumer devices, today announces successful preliminary results of its pivotal hypoxia trial, which was completed in conjunction with the university of california, san francisco (ucsf) to assess the accuracy of its smart ring's blood oxygen saturation (spo2) and heart rate data.
MOVE Ratings Summary
MOVE Quant Ranking